Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.51 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.51 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.48 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29313756 | 0.89 | EGFR (0.58) | EGFRIRAK4MAP3K7IRAK1NPC1 | |
| SCHEMBL21025638 | 0.85 | MAP3K7 (0.69) | EGFRIRAK4MAP3K7IRAK1KCNK3 | |
| SCHEMBL29313493 | 0.80 | MAP3K7 (0.77) | EGFRIRAK4MAP3K7IRAK1RAB9A | |
| SCHEMBL16755391 | 0.80 | EGFR (0.61) | EGFRNPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL29313506 | 0.80 | IRAK4 (0.62) | EGFRIRAK4 | |
| SCHEMBL29313489 | 0.79 | IRAK4 (0.66) | EGFRIRAK4MAP3K7IRAK1RAB9A | |
| SCHEMBL16755407 | 0.78 | EGFR (0.53) | EGFRNPC1RAB9ALMNAMEN1 | |
| SCHEMBL16755417 | 0.77 | EGFR (0.80) | EGFRKCNK3KCNK9LMNA | |
| SCHEMBL5089620 | 0.77 | RAB9A (0.70) | NPC1RAB9ALMNAMAPTMEN1 | |
| SCHEMBL20985290 | 0.77 | EGFR (0.67) | EGFRIRAK4MAP3K7IRAK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | EGFR 349/4885IRAK4 2/4885MAP3K7 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.